Efficacy and safety of rituximab biosimilars or reference product as first-line treatment in patients with low-tumour-burden follicular lymphoma: A systematic review and meta-analysis.
Journal of clinical pharmacy and therapeutics（2022）
摘要
Our study concluded that the efficacy and safety of rituximab biosimilars in the treatment of LTB-FL are highly similar to those of the original drug.
更多查看译文
关键词
biosimilar,efficacy,follicular lymphoma,meta-analysis,rituximab,safety
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要